drugset
drugset / Trial / NCT02262533

Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

NCT02262533 ↗

Phase 1 Completed 15 enrolled Bristol-Myers Squibb Pfizer · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.

Timeline

Start
2007-06
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 10 mg Oral
Subject Atenolol Other / unclassified 100 mg Oral

Indications

No indication recorded.